Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Epirubicin directly promotes hepatitis B virus (HBV) replication in stable HBV-expressing cell lines: a novel mechanism of HBV reactivation following anticancer chemotherapy.

Xu L, Tu Z, Xu G, Wang Y, Pan W, Zhan X, Luo Q, Huang Y, Chen J, Huang A.

Mol Med Rep. 2014 Apr;9(4):1345-50. doi: 10.3892/mmr.2014.1973. Epub 2014 Feb 20.

PMID:
24566498
2.

S-phase arrest after vincristine treatment may promote hepatitis B virus replication.

Xu L, Tu Z, Xu G, Hu JL, Cai XF, Zhan XX, Wang YW, Huang Y, Chen J, Huang AL.

World J Gastroenterol. 2015 Feb 7;21(5):1498-509. doi: 10.3748/wjg.v21.i5.1498.

4.

Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.

Steinberg JL, Yeo W, Zhong S, Chan JY, Tam JS, Chan PK, Leung NW, Johnson PJ.

J Med Virol. 2000 Mar;60(3):249-55.

PMID:
10630955
5.

Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study.

Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ.

J Med Virol. 2003 Aug;70(4):553-61.

PMID:
12794717
6.

Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.

Matsui T, Kang JH, Nojima M, Tomonari A, Aoki H, Yamazaki H, Yane K, Tsuji K, Andoh S, Andoh S, Sakai H, Maemori M, Maguchi H, Tanaka Y.

J Med Virol. 2013 Nov;85(11):1900-6. doi: 10.1002/jmv.23694. Epub 2013 Aug 7.

PMID:
23926082
7.

Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.

Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD.

J Clin Oncol. 2013 Aug 1;31(22):2765-72. doi: 10.1200/JCO.2012.48.5938. Epub 2013 Jun 17.

PMID:
23775967
9.

The metabolic regulator PGC-1α links anti-cancer cytotoxic chemotherapy to reactivation of hepatitis B virus.

Mouler Rechtman M, Burdelova EO, Bar-Yishay I, Ben-Yehoyada M, Fishman S, Halpern Z, Shlomai A.

J Viral Hepat. 2013 Jan;20(1):34-41. doi: 10.1111/j.1365-2893.2012.01622.x. Epub 2012 May 22.

PMID:
23231082
10.

Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.

Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N.

J Clin Oncol. 2010 Dec 1;28(34):5097-100. doi: 10.1200/JCO.2010.29.7531. Epub 2010 Sep 13. Retraction in: J Clin Oncol. 2011 Sep 20;29(27):3720.

PMID:
20837949
11.

Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.

Simpson ND, Simpson PW, Ahmed AM, Nguyen MH, Garcia G, Keeffe EB, Ahmed A.

J Clin Gastroenterol. 2003 Jul;37(1):68-71.

PMID:
12811213
12.

The difficulties of managing severe hepatitis B virus reactivation.

Roche B, Samuel D.

Liver Int. 2011 Jan;31 Suppl 1:104-10. doi: 10.1111/j.1478-3231.2010.02396.x. Review.

PMID:
21205146
13.

Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein.

Gordien E, Rosmorduc O, Peltekian C, Garreau F, Bréchot C, Kremsdorf D.

J Virol. 2001 Mar;75(6):2684-91.

14.

Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.

Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS.

Eur J Cancer. 2013 Nov;49(16):3486-96. doi: 10.1016/j.ejca.2013.07.006. Epub 2013 Aug 1.

PMID:
23910494
15.

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK.

J Clin Oncol. 2009 Feb 1;27(4):605-11. doi: 10.1200/JCO.2008.18.0182. Epub 2008 Dec 15.

PMID:
19075267
16.

Reactivation of hepatitis B virus associated with chemotherapy and immunosuppressive agent.

Wijaya I, Hasan I.

Acta Med Indones. 2013 Jan;45(1):61-6. Review.

17.

Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.

Alexopoulou A, Theodorou M, Dourakis SP, Karayiannis P, Sagkana E, Papanikolopoulos K, Archimandritis AJ.

J Viral Hepat. 2006 Sep;13(9):591-6.

PMID:
16907845
18.

A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?

Long M, Jia W, Li S, Jin L, Wu J, Rao N, Feng H, Chen K, Deng H, Liu F, Su F, Song E.

Breast Cancer Res Treat. 2011 Jun;127(3):705-12. doi: 10.1007/s10549-011-1455-9. Epub 2011 Mar 29.

PMID:
21445574
19.

High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy.

Zhong S, Yeo W, Schroder C, Chan PK, Wong WL, Ho WM, Mo F, Zee B, Johnson PJ.

J Viral Hepat. 2004 Jan;11(1):55-9.

PMID:
14738558
20.

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.

Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Tien HF, Chao TY, Chen LT, Whang-Peng J; Lymphoma Committee of Taiwan Cooperative Oncology Group.

Hepatology. 2003 Jun;37(6):1320-8.

PMID:
12774010

Supplemental Content

Support Center